Incyte Biosciences Distribution BV

1. Primary objective: To evaluate the efficacy of Tafa combined with Len and orelabrutinib in the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma. 2. Secondary objectives: 1) To evaluate other efficacy indicators of Tafa combined with Len and orelabrutinib in the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma. 2) To evaluate the safety of Tafa combined with Len and orelabrutinib in the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma. 3. Other objectives: 1) To explore the pharmacokinetic (PK) characteristics of Tafa and orelabrutinib. 2) To evaluate the immunogenicity of Tafa.

To evaluate the safety and tolerability of Tafasitamab and Lenalidomide combined with GemOx in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma, and to compare the efficacy and safety of Tafasitamab and Lenalidomide combined with GemOx in patients with relapsed/refractory diffuse large B-cell lymphoma

Main purpose: To evaluate the clinical efficacy of Tafa combined with Len in the treatment of patients with relapsed or refractory DLBCL. Secondary objectives: 1. To further evaluate the effectiveness of Tafa combined with Len in the treatment of patients with relapsed or refractory DLBCL through other efficacy indicators; 2. To evaluate the safety and tolerability of Tafa combined with Len in the treatment of patients with relapsed or refractory DLBCL; 3. To evaluate the immunogenicity of Tafa; 4. To evaluate the pharmacokinetic (PK) characteristics of Tafa.